Nikolay Savchuk
COO & DirectorDr. Nikolay Savchuk PhD, is Director and Chief Operating Officer of Clywedog Therapeutics, Inc. Dr. Savchuk serves as President, Chief Operating Officer and Director at Lomond Therapeutics Holdings, Inc. since November 01, 2024. He has served as Chief Operating Officer and Director of Traws Pharma, Inc. since April 01, 2024. He also serves as a Partner at Teal Ventures, a venture capital fund he founded in October 2018 and as Managing Director and Founder at Torrey Pines Investment LLC, an investment firm, since November 2002. Since March 2019, he has been a Member at i2020 Accelerator, an accelerator program backed by Torrey Pines Investment. Dr. Savchuk serves as Director at Avineuro Pharmaceuticals, Inc. and Lomond Therapeutics, Inc., where he also previously served as a Director since January 2020 prior to its merger into Lomond Therapeutics Holdings, Inc. on November 1, 2024. He has been the Chief Executive Officer and Director of Clywedog Therapeutics, Inc. since December 2020 and also serves as Chief Executive Officer of Dinas Therapeutics, Inc. since March 2022. In addition, he has served as President and Chief Executive Officer of Bala Therapeutics, Inc. since June 2018 and as President and Chief Executive Officer of Eil Therapeutics, Inc. since February 2020. He also serves as Chief Operating Officer and President of Eilean Therapeutics, LLC since September 2022. He served as Chief Executive Officer of ChemDiv, Inc. from April 2008 to January 2022 and has served as Chairman of its board since November 2013, having led its business team since 1998. During his tenure at ChemDiv, he held positions of increasing responsibility including Director of Information Technologies, Vice President of Business Development and Director. Dr. Savchuk serves as Chairman of the Board of Viriom, Inc. since November 2015 and Chairman of its Scientific Advisory Board. He is also Executive Chairman of Chromis Therapeutics and serves as Chairman of SatRx, NewVac Ltd. and TeaRx Ltd. He serves on the board of ChemRar High-Tech Center and is Chairman of Chemical Diversity Research Institute. Additionally, he serves as Director of AllaChem, LLC and is affiliated with the Moscow Institute of Physics and Technology as Director for Strategic Development and board member of its BioPharmCluster. He serves on the Board of Celyn Therapeutics and Gwynant Therapeutics since September 2021 and previously served as Director of Avelas BioSciences, Inc. from January 9, 2014 to August 18, 2016. Dr. Savchuk is Co-Founder and Member of the Advisory Board of Initiative PhysTech 21. He has served as Advisor and Expert to the Agency of Strategic Initiatives and is a Member of the Expert Council of the Agency of Strategic Initiatives and New Projects of the Russian Government. He has also been a Member of the U.S.-Russian Bilateral Presidential Commission’s Working Group on Health and an industry representative to the Russian government’s Pharma 2020 initiative. Earlier in his career, Dr. Savchuk co-founded the INEL Group of IT and media companies in Singapore and Russia and held various business and research management roles in the IT industry across both regions. Dr. Savchuk is a serial entrepreneur and experienced international investor in healthcare and IT industries. His primary areas of interest include life sciences, rational drug design, drug development and digital health technologies. He has led and managed successful investments in numerous pharmaceutical and drug development companies. Dr. Savchuk is the author of over 60 scientific papers and research publications and is an inventor on more than 100 patents. He holds a Master of Science degree in Physics (1994) and a Ph.D. in Physics and Applied Mathematics (2000) from the Moscow Institute of Physics and Technology.
Positions
- Company NameTraws Pharma, Inc.Stock CodeTRAWPositionCOO & DirectorColleagues
- IDIain D. DukesCEO, Secretary & Director
- JEJack E. StoverIndependent Chairman
- CDCharles David PauzaChief Scientific Officer of Virology
- CPCharles ParkerChief Financial Officer
- VMVictor Mandia MoyoChief Medical Officer of Oncology
- MTMary Teresa ShoemakerIndependent Director
- TCTrafford ClarkeIndependent Director
